体内
谷氨酸羧肽酶Ⅱ
抗原
前列腺特异性抗原
前列腺
膜
铜
化学
癌症研究
医学
免疫学
内科学
生物
生物化学
癌症
生物技术
有机化学
作者
Szilvia Bunda,Ibolya Kálmán-Szabó,Dezső Szikra,Anikó Fekete,Dániel Szücs,Judit Szabó,György Trencsényi,Zita Képes,Ferenc K. Kálmán
标识
DOI:10.1021/acsptsci.4c00685
摘要
The introduction of radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) has revolutionized the molecular imaging of prostate cancer (PCa); however, due to the potential downsides of the commonly used labeling entities (gallium-68/fluorine-18), the role of alternative isotopes is emerging. Given the desirable physical characteristics of positron emitter copper-61 (61Cu), herein, a novel PSMA PET probe using the recently introduced KFTG chelator was developed and tested in vivo ([61Cu]-Cu-KFTG-PSMA). Pharmacokinetics was assessed in PSMA+ LNCaP PCa xenografts and healthy counterparts using micro-PET imaging, biodistribution, and competition studies. The uptake of [61Cu]-Cu-KFTG-PSMA in LNCaP tumor lesions showed a trend to increase from 30 to 180 min post-injection (SUVmean: 1.50 ± 0.19-2.18 ± 0.25). In comparison, healthy organs demonstrated low radioactivity and fast body clearance, yielding better contrast for later time point images. Likewise, gradually increasing tumor retention was observed ex vivo as well (11.4 ± 1.4, 12.6 ± 1.6, and 13.8 ± 2.1%ID/g at 30, 90, and 180 min post-injection, respectively); however, some gastrointestinal organs presented moderate early time point accumulation. Followed by pretreatment with cold PSMA, blocked LNCaP tumors showed hardly any radioactivity, which further confirmed high target specificity both in vivo and ex vivo.
科研通智能强力驱动
Strongly Powered by AbleSci AI